Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BNTC

BNTC - Benitec Biopharma Ltd Stock Price, Fair Value and News

$12.11-0.44 (-3.51%)
Market Closed

6/100

BNTC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

BNTC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$9.98

Target 3M

$11.23

Target 6M

$10.61

BNTC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BNTC Price Action

Last 7 days

-0.1%

Last 30 days

-10.2%

Last 90 days

-25.1%

Trailing 12 Months

12.6%

BNTC RSI Chart

BNTC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BNTC Valuation

Market Cap

410.1M

Price/Earnings (Trailing)

-11.89

Price/Sales (Trailing)

5.9K

Price/Free Cashflow

-18.34

BNTC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$9.98

Target 3M

$11.23

Target 6M

$10.61

BNTC Fundamentals

BNTC Revenue

Revenue (TTM)

75.0K

BNTC Earnings

Earnings (TTM)

-34.5M

Earnings Growth (Yr)

-77.21%

Earnings Growth (Qtr)

-1.82%

BNTC Profitability

Return on Equity

-36.84%

Return on Assets

-35.91%

Free Cashflow Yield

-5.45%

BNTC Investor Care

Shares Dilution (1Y)

45.85%

Diluted EPS (TTM)

-1

BNTC Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
2023116.0K75.0K00
202282.0K74.0K087.0K
20211.8M123.0K0102.5K
20208.7M7.0M5.3M3.6M
2019012.2M10.5M0
Get all data in R, Python etc through our Historical Stock Data APIs

About Benitec Biopharma Ltd

BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
 CEO
 WEBSITEhttps://benitec.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES18

Benitec Biopharma Ltd Frequently Asked Questions

BNTC is the stock ticker symbol of Benitec Biopharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Benitec Biopharma Ltd is 410.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BNTC's fair value in chart for subscribers.

The fair value guage provides a quick view whether BNTC is over valued or under valued. Whether Benitec Biopharma Ltd is cheap or expensive depends on the assumptions which impact Benitec Biopharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNTC.

As of Wed Jan 28 2026, BNTC's PE ratio (Price to Earnings) is -11.89 and Price to Sales (PS) ratio is 5.94 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNTC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Benitec Biopharma Ltd has provided -0.351 (multiply by 100 for percentage) rate of return.